TORONTO - BIO 2002 is a unmatched opportunity for those involved in the sector to mingle, network, press the flesh and generally discuss the topic that brought the masses here: biotechnology. It also is the grandest stage in the industry, and provides instant access to the ears of the most revered names in the business.
TORONTO - BIO 2002 is a unmatched opportunity for those involved in the sector to mingle, network, press the flesh and generally discuss the topic that brought the masses here: biotechnology. It also is the grandest stage in the industry, and provides instant access to the ears of the most revered names in the business.
Neurocrine Biosciences Inc. kicked off its fifth Phase III trial of its insomnia product - but the first with the modified-release version - and said it was issued a patent for the chemical composition of the drug that would give the company patent exclusivity until 2020. (BioWorld Today)
Neurocrine Biosciences Inc. kicked off its fifth Phase III trial of its insomnia product - but the first with the modified-release version - and said it was issued a patent for the chemical composition of the drug that would give the company patent exclusivity until 2020. (BioWorld Today)
